Home > Oncology > ASCO 2019 > Lung Cancer > First-in-human study shows IL1RAP-targeting drug safe in solid tumours

First-in-human study shows IL1RAP-targeting drug safe in solid tumours

Presented By
Dr Ahmad Awada, Institut Jules Bordet, Belgium
Conference
ASCO 2019
Medical writer: Leah Lawrence The interleukin-1 (IL-1) receptor accessory protein (IL1RAP)-targeting CAN04 (nidanilimab) was well tolerated, with infusion-related reactions as the most common treatment-related adverse events occurring in a first-in-human study (Abstract 2504) presented on June 2. “IL1RAP is required in order to activate IL-1 receptor signaling,” which is critical in solid tumours, presenter Ahmad Awada, MD, PhD, of Institut Jules Bordet, Belgium, said. Chronic tumour IL-1 signaling is involved in resistance to cancer therapies, immune evasion, and metastases. CAN04 is a humanized and antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 antibody targeting IL1RAP with two modes of action: blocking IL-1 alpha and beta signaling and triggering ADCC. This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or colorectal cancer (12 patients). In...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on